多西他赛联合吡柔比星治疗乳腺癌的临床效果及对患者肿瘤标志物水平、复发率及生存率的影响分析

The clinical effect of docetaxel combined with pirarubicin in the treatment of breast cancer and its influence on the level of tumor markers,recurrence rate and survival rate of patients

目的分析多西他赛联合吡柔比星治疗乳腺癌的临床效果及对肿瘤标志物水平、复发率及生存率的影响。方法选取本院2014年2月至2016年3月于乳腺科进行治疗的乳腺癌患者102例作为研究对象,根据治疗方法不同分为联合组和对照组,各51例。对照组给予多西他赛,联合组在对照组的基础上联合吡柔比星。比较两组临床疗效、血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)水平、生存率和复发率。结果联合组治疗总有效率为76.47%,显著高于对照组的56.86%(P<0.05);治疗后,两组血清肿瘤标志物均显著低于治疗前(P<0.05),联合组CRA和CA125低于对照组,但差异无统计学意义,联合组CA153显著低于对照组(P<0.05)。联合组复发率为19.61%,显著低于对照组的37.25%(P<0.05),联合组1、2、3年生存率为72.55%、60.78%和39.22%,高于对照组的60.78%、49.02%和27.45%,但差异无统计学意义。结论多西他赛联合吡柔比星治疗乳腺癌患者,可降低血液肿瘤标志物水平,显著提升患者的生存率及临床治疗效果,并降低患者的复发率,值得临床推广应用。

Objective To analyze the clinical effect of docetaxel combined with pirarubicin in the treatment of breast cancer and its influence on the level of tumor markers,recurrence rate and survival rate.Methods 102 breast cancer patients who were treated in the department of breast cancer in our hospital from February 2014 to March 2016 were selected as the research subjects.According to different treatment methods,they were divided into combination group and control group,with 51 cases in each group.The control group was given docetaxel,and the combination group was combined with pirarubicin on the basis of the control group.The clinical efficacy,serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),survival rate and recurrence rate were compared between the two groups.Results The total effective rate of the combination group was 76.47%,which was significantly higher than 56.86%of the control group(P<0.05);after treatment,the serum tumor markers of the two groups were significantly lower than those before treatment(P<0.05).The CRA and CA125 in the combination group were lower than the control group,but the difference was not statistically significant.The CA153 of the combination group was significantly lower than the control group(P<0.05).The recurrence rate of the combination group was 19.61%,which was significantly lower than 37.25%in the control group(P<0.05).The 1,2,3-year survival rates of the combination group were 72.55%,60.78%and 39.22%,which were higher than 60.78%,49.02%and 27.45%in the control group,but the difference was not statistically significant.Conclusion Docetaxel combined with pirarubicin therapy has positive effect on reducing the level of blood tumor markers in breast cancer patients,significantly improving the survival rate and clinical treatment effect of patients,and reducing the recurrence rate of patients.It is worthy of clinical application.